INT11949

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.09
First Reported 1991
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 11
Total Number 11
Disease Relevance 8.13
Pain Relevance 0.85

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (Apob) transport (Apob) extracellular space (Apob)
extracellular region (Apob) endoplasmic reticulum (Apob) enzyme binding (Apob)
Anatomy Link Frequency
plasma 1
Apob (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Bile 27 95.92 Very High Very High Very High
tolerance 3 81.16 Quite High
Pain 13 79.92 Quite High
headache 8 73.92 Quite High
peptic ulcer disease 1 58.40 Quite High
Central nervous system 1 45.84 Quite Low
Angina 1 25.00 Low Low
nud 1 12.16 Low Low
withdrawal 3 11.84 Low Low
cva 25 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 165 100.00 Very High Very High Very High
Coronary Artery Disease 29 97.20 Very High Very High Very High
Hyperlipidemia 37 96.36 Very High Very High Very High
Reprotox - General 1 53 92.44 High High
Diabetes Mellitus 162 89.00 High High
Lipid Metabolism Disorders 1 84.84 Quite High
Myalgia 8 79.92 Quite High
Congenital Anomalies 6 77.44 Quite High
Myocardial Infarction 28 74.88 Quite High
Headache 8 73.92 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Results showed that only toremifene had a beneficial effect on lipid profile, indicated by a decrease in total cholesterol, LDL cholesterol, triglycerides, and apolipoprotein B, and an increase in HDL cholesterol and apolipoprotein A1.
Negative_regulation (decrease) of apolipoprotein B associated with disorder of lipid metabolism
1) Confidence 0.09 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001222 Disease Relevance 1.07 Pain Relevance 0
The reductions in total cholesterol (TC) (21%), low-density lipoprotein cholesterol (LDL-C) (28%), and apolipoprotein B (apo B) (22%) were comparable for the lovastatin 20-mg and pravastatin 20-mg groups.
Negative_regulation (reductions) of apolipoprotein B associated with disorder of lipid metabolism
2) Confidence 0.09 Published 1992 Journal Clin Ther Section Abstract Doc Link 1611649 Disease Relevance 0.76 Pain Relevance 0
Consistent with a significant reduction in apoB (11.8%) in GLOWS [76], improvements in atherogenic lipoprotein subclasses measured by NMR were also reported with colesevelam.
Negative_regulation (reduction) of apoB
3) Confidence 0.06 Published 2010 Journal Lipids Health Dis Section Body Doc Link PMC3022752 Disease Relevance 0.42 Pain Relevance 0.12
The decrease in apolipoprotein B was 28.4%, of basal, with S 16.4% and in P 19.2%.
Negative_regulation (decrease) of apolipoprotein B associated with disorder of lipid metabolism
4) Confidence 0.04 Published 1991 Journal Eur. J. Clin. Pharmacol. Section Abstract Doc Link 1904357 Disease Relevance 0.84 Pain Relevance 0.30
Cerivastatin 0.8 mg also reduced mean total cholesterol by 29.9%, apolipoprotein B by 33.2% and median triglycerides by 22.9% (all P < 0.0001).
Negative_regulation (reduced) of apolipoprotein B associated with disorder of lipid metabolism
5) Confidence 0.04 Published 2000 Journal J. Int. Med. Res. Section Abstract Doc Link 10898118 Disease Relevance 1.10 Pain Relevance 0.05
Niacin also favorably influences other lipid parameters including lipoprotein(a) [Lp(a)], alimentary lipemia, familial defective apolipoprotein B-100 and small dense LDL.
Negative_regulation (defective) of apolipoprotein B-100 associated with disorder of lipid metabolism
6) Confidence 0.03 Published 1996 Journal Coron. Artery Dis. Section Abstract Doc Link 8853585 Disease Relevance 1.30 Pain Relevance 0.15
Its effects are similar in most patient groups, with 20 to 80 mg/day reducing LDL-C by 22 to 36%, triglycerides (TG) by 12 to 18% and apolipoprotein B by 19 to 28% and increasing high density lipoprotein cholesterol by 3.3 to 5.6%.
Negative_regulation (reducing) of apolipoprotein B associated with disorder of lipid metabolism
7) Confidence 0.02 Published 1999 Journal Drugs Section Abstract Doc Link 10235694 Disease Relevance 0.71 Pain Relevance 0.08
At two years, both doses of lasofoxifene resulted in greater reductions in LDL-C and total cholesterol levels when compared with raloxifene and placebo.85 Moreover lasofoxifene-treated women showed significantly greater decreases in Apo B100 (?
Negative_regulation (decreases) of Apo B100 associated with disorder of lipid metabolism
8) Confidence 0.02 Published 2010 Journal Core evidence Section Body Doc Link PMC2899785 Disease Relevance 0.17 Pain Relevance 0.07
Apolipoprotein B levels declined in both treatment groups (-31.8%, p < 0.001 with combination therapy versus -29.8%, p < 0.001 with atorvastatin monotherapy).
Negative_regulation (declined) of Apolipoprotein B associated with disorder of lipid metabolism
9) Confidence 0.01 Published 2009 Journal Lipids Health Dis Section Body Doc Link PMC2803170 Disease Relevance 0.67 Pain Relevance 0
In parallel, apolipoprotein B concentrations were significantly reduced by a weighted average of 0·087 (0·004) g/L.
Negative_regulation (reduced) of apolipoprotein B associated with disorder of lipid metabolism
10) Confidence 0.01 Published 2010 Journal Lancet Section Body Doc Link PMC2988223 Disease Relevance 0.36 Pain Relevance 0.08
Furthermore, significant reductions in fasting plasma glucose, fructosamine, total cholesterol, non–HDL cholesterol, and apolipoprotein B were demonstrated in the colesevelam relative to placebo group at week 26.
Negative_regulation (reductions) of apolipoprotein B in plasma associated with disorder of lipid metabolism
11) Confidence 0.01 Published 2008 Journal Diabetes Care Section Abstract Doc Link PMC2494667 Disease Relevance 0.49 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox